J-Pharma Co., Ltd.
↗Tokyo, Japan
J-Pharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Japan, specializing in the research and development of novel drugs targeting SLC (Solute Carrier) transporters, particularly L-type amino acid transporter 1 (LAT1). The company leverages intellectual property developed at Kyorin University to address unmet medical needs in oncology and other therapeutic areas.
J-Pharma's lead candidate, nanvuranlat, is a selective LAT1 inhibitor currently in clinical development for biliary tract cancer and other malignancies. The company is actively pursuing global clinical trials and strategic partnerships to advance its pipeline, which also includes JPH034 for neurological conditions like multiple sclerosis.
CLASSIFICATION
SIZE & FINANCIALS
Founded:2005
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:JIC Venture Growth Investments, Eight Roads Ventures Japan, F-Prime Capital, Newton Biocapital, Pricaf Privee SA, OHARA Pharmaceutical Co., Ltd., SPERAPHARMA, Inc.
STOCK
Exchange:Tokyo Stock Exchange
Market Cap:$0.07B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Kyorin University (Technology origin), Osaka University, Yokohama City University, Georgetown University, Kanazawa University, OHARA Pharmaceutical Co., Ltd.
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Hitoshi Endou - Founder
Scientific Founders:Hitoshi Endou
LINKS
Website:j-pharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of J-Pharma Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with J-Pharma Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.